Medtronic and Eli Lilly in Drug-Device Pact for Parkinson’s Disease
By Heather Cartwright
Pharma Deals Review: Vol 2011 Issue 4 (Table of Contents)
Published: 30 Apr-2011
DOI: 10.3833/pdr.v2011.i4.1464 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
Eli Lilly has formed an early-stage, drug-device collaboration with the world’s largest medical device maker, Medtronic, to research and develop a Parkinson’s disease treatment using Lilly’s modified form of glial cell-derived neurotrophic factor (GDNF) and Medtronic’s implantable drug infusion device. Previous attempts to deliver GDNF effectively across the blood-brain barrier have been unsuccessful and the companies will hope to overcome the technical challenges presented by this novel approach to the treatment of Parkinson’s disease.
Copyright: © IQVIA 2018